THC Memory & Reward Learning Pilot

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Tetrahydrocannabidiol (THC) is the psychoactive chemical in cannabis that makes people high. This study aims to dissect acute impairment of various forms of memory and learning by THC in cannabis compared to placebo. Impairment will be assessed via a short cognitive test battery and then subjects will complete four tasks in the fMRI scanner.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hartford Hospital
• Collaborator: Yale University

Criteria

Inclusion Criteria:

• 18-55 years old

• Right handed

• CNB use within past 2 years and felt "high" when used

• Able to read, speak, and understand English

• Able and willing to provide written informed consent, and willing to commit to study protocol.

Exclusion Criteria:

• Current marijuana tolerance, desire to cut down, or cravings to sue during periods of abstinence.

• Strongly left-handed

• Positive screen for drug or alcohol (except CNB) on test day will result in rescheduling the appointment

• History of adverse effects with CNB

• CNB users who are abstaining

• Report of any psychotic disorder in a first degree relative

• IQ < 80 on the Wechsler Abbreviated Scale of Intelligence

• Inability to comprehend written instructions using the WRAT-4 reading achievement test

• Pregnant, breastfeeding, and ineffective birth control methods.

• Unable or unsafe to have an MRI

• Serious medical, neuro-ophthalmological, or neurological illness (e.g. cancer, seizure disorders, encephalopathy

• History of head trauma with loss of consciousness > 30 minutes or concussion lasting 30 days.

• Focal brain lesion seen on structural MRI

• Any medical/neurological condition that could compromise neurocognitive performance (e.g. epilepsy, multiple sclerosis, fetal alcohol syndrome).

• Anyone deemed unsafe to study personnel for any reason